Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality
- PMID: 35367784
- PMCID: PMC9096622
- DOI: 10.1016/j.ctrv.2022.102375
Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality
Abstract
Background: Adjuvant and neoadjuvant breast cancer treatments can reduce breast cancer mortality but may increase mortality from other causes. Information regarding treatment benefits and risks is scattered widely through the literature. To inform clinical practice we collated and reviewed the highest quality evidence.
Methods: Guidelines were searched to identify adjuvant or neoadjuvant treatment options recommended in early invasive breast cancer. For each option, systematic literature searches identified the highest-ranking evidence. For radiotherapy risks, searches for dose-response relationships and modern organ doses were also undertaken.
Results: Treatment options recommended in the USA and elsewhere included chemotherapy (anthracycline, taxane, platinum, capecitabine), anti-human epidermal growth factor 2 therapy (trastuzumab, pertuzumab, trastuzumab emtansine, neratinib), endocrine therapy (tamoxifen, aromatase inhibitor, ovarian ablation/suppression) and bisphosphonates. Radiotherapy options were after breast conserving surgery (whole breast, partial breast, tumour bed boost, regional nodes) and after mastectomy (chest wall, regional nodes). Treatment options were supported by randomised evidence, including > 10,000 women for eight treatment comparisons, 1,000-10,000 for fifteen and < 1,000 for one. Most treatment comparisons reduced breast cancer mortality or recurrence by 10-25%, with no increase in non-breast-cancer death. Anthracycline chemotherapy and radiotherapy increased overall non-breast-cancer mortality. Anthracycline risk was from heart disease and leukaemia. Radiation-risks were mainly from heart disease, lung cancer and oesophageal cancer, and increased with increasing heart, lung and oesophagus radiation doses respectively. Taxanes increased leukaemia risk.
Conclusions: These benefits and risks inform treatment decisions for individuals and recommendations for groups of women.
Keywords: Adjuvant treatments; Breast cancer; Neoadjuvant treatments; Treatment benefits; Treatment harms.
Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures
Similar articles
-
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.Lancet. 2005 May 14-20;365(9472):1687-717. doi: 10.1016/S0140-6736(05)66544-0. Lancet. 2005. PMID: 15894097
-
The curability of breast cancer and the treatment of advanced disease.Eur J Nucl Med Mol Imaging. 2004 Jun;31 Suppl 1:S149-61. doi: 10.1007/s00259-004-1538-5. Epub 2004 Apr 24. Eur J Nucl Med Mol Imaging. 2004. PMID: 15107948 Review.
-
Treatment of breast cancer in countries with limited resources.Breast J. 2003 May-Jun;9 Suppl 2:S67-74. doi: 10.1046/j.1524-4741.9.s2.6.x. Breast J. 2003. PMID: 12713499
-
Breast cancer (non-metastatic).BMJ Clin Evid. 2007 Dec 4;2007:0102. BMJ Clin Evid. 2007. PMID: 19450345 Free PMC article. Review.
-
Systemic treatment of patients with early breast cancer: recent updates and state of the art.Breast. 2019 Nov;48 Suppl 1:S7-S20. doi: 10.1016/S0960-9776(19)31115-4. Breast. 2019. PMID: 31839166 Review.
Cited by
-
Comparison of Effects Between Telerehabilitation and In-Person Rehabilitation After Breast Cancer Surgery: A Randomized Controlled Study.Integr Cancer Ther. 2024 Jan-Dec;23:15347354241256314. doi: 10.1177/15347354241256314. Integr Cancer Ther. 2024. PMID: 39223789 Free PMC article. Clinical Trial.
-
Closing the Gaps: An Integrative Review of Yoga's Benefits for Lymphedema in Breast Cancer Survivors.Life (Basel). 2024 Aug 11;14(8):999. doi: 10.3390/life14080999. Life (Basel). 2024. PMID: 39202741 Free PMC article. Review.
-
The Role of Epithelial-to-Mesenchymal Transition Transcription Factors (EMT-TFs) in Acute Myeloid Leukemia Progression.Biomedicines. 2024 Aug 21;12(8):1915. doi: 10.3390/biomedicines12081915. Biomedicines. 2024. PMID: 39200378 Free PMC article. Review.
-
Prognostic and clinicopathological significance of fibrinogen-to-albumin ratio (FAR) in patients with breast cancer: a meta-analysis.World J Surg Oncol. 2024 Aug 24;22(1):220. doi: 10.1186/s12957-024-03506-2. World J Surg Oncol. 2024. PMID: 39182155 Free PMC article.
-
Continuous exposure to doxorubicin induces stem cell-like characteristics and plasticity in MDA-MB-231 breast cancer cells identified with the SORE6 reporter.Cancer Chemother Pharmacol. 2024 Aug 24. doi: 10.1007/s00280-024-04701-4. Online ahead of print. Cancer Chemother Pharmacol. 2024. PMID: 39180549
References
-
- Centre for Evidence-based Medicine. Centre for Evidence-based medicine – Levels of evidence. https://www.cebm.net/2009/06/oxford-centre-evidence-based-medicine-level... 2009 [accessed 22 Aug 2019].
-
- Early Breast Cancer Trialists' Collaborative Group. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 2011b;378:1707-16. 10.1016/S0140-6736(11)61629-2. - DOI - PMC - PubMed
-
- PREDICT, 2017. https://breast.predict.nhs.uk/ [accessed 22 Aug 2019].
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical